American Society of Hirudotherapy

Guidelines for the treatment of acute ischaemic stroke.

Review published in Neurologia (Barcelona, Spain) (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Practice guidelineClinical TrialsDrug DevelopmentAlonso de Leciñana et al. · Neurologia (Barcelona, Spain), 2011

Abstract

INTRODUCTION: Update of Acute Ischaemic Stroke Treatment Guidelines of the Spanish Neurological Society based on a critical review of the literature. Recommendations are made based on levels of evidence from published data and studies. DEVELOPMENT: Organized systems of care should be implemented to ensure access to the optimal management of all acute stroke patients in stroke units. Standard of care should include treatment of blood pressure (should only be treated if values are over 185/105 mmHg), treatment of hyperglycaemia over 155 mg/dl, and treatment of body temperature with antipyretic drugs if it rises above 37.5 °C. Neurological and systemic complications must be prevented and promptly treated. Decompressive hemicraniectomy should be considered in cases of malignant cerebral oedema. Intravenous thrombolysis with rtPA should be administered within 4.5 hours from symptom onset, except when there are contraindications. Intra-arterial pharmacological thrombolysis can be considered within 6 hours, and mechanical thrombectomy within 8 hours from onset, for anterior circulation strokes, while a wider window of opportunity up to 12-24 hours is feasible for posterior strokes. There is not enough evidence to recommend routine use of the so called neuroprotective drugs. Anticoagulation should be administered to patients with cerebral vein thrombosis. Rehabilitation should be started as early as possible. CONCLUSION: Treatment of acute ischaemic stroke includes management of patients in stroke units. Systemic thrombolysis should be considered within 4.5 hours from symptom onset. Intra-arterial approaches with a wider window of opportunity can be an option in certain cases. Protective and restorative therapies are being investigated.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeGuidelineJournal ArticleReview
Indexed MeSH termsBrain IschemiaHumansIntracranial EmbolismStrokeThrombectomyThrombolytic Therapy

Summary

Update of Acute Ischaemic Stroke Treatment Guidelines of the Spanish Neurological Society based on a critical review of the literature. Recommendations are made based on levels of evidence from published data and studies. Organized systems of care should be implemented to ensure access to the optimal management of all acute stroke patients in stroke units.

Why This Matters for Hirudotherapy

This Spanish Neurological Society guideline updates acute ischaemic stroke management based on a critical literature review, recommending organized stroke-unit care, blood-pressure treatment only above 185/105 mmHg, management of hyperglycaemia and fever, intravenous rtPA thrombolysis within 4.5 hours (intra-arterial thrombolysis within 6 hours and mechanical thrombectomy within 8 hours for anterior-circulation strokes, with wider windows posteriorly), and anticoagulation for cerebral vein thrombosis, while finding insufficient evidence for routine neuroprotective drugs. For ASH it is peripheral context within the thrombosis/anticoagulation evidence base: it documents how acute arterial thrombosis is treated pharmacologically and procedurally, but addresses standard thrombolytics, antithrombotics, and devices, not medicinal-leech therapy. As an evidence-graded consensus guideline (a synthesis of others' studies, now over a decade old), it provides framing only and makes no statement about hirudotherapy; refer to current guidelines for present-day practice.

Citation

Guidelines for the treatment of acute ischaemic stroke.

Alonso de Leciñana et al. · Neurologia (Barcelona, Spain), 2011

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.